A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors
Recruiting now · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumors
In brief
This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options are available. Once the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of single agent LCB02A is determined, the study will proceed to Phase 2 expansion cohorts in selected tumor types.
Key facts
- Study ID
- NCT07460375
- Run by
- LigaChem Biosciences, Inc.
- People needed
- 191
- Starts
- 2026-08-01
- Expected to finish
- 2030-08-01
- Last updated by the study team
- 2026-07-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- START New York - Long Island — Lake Success, New York, United States (enrolling)
- Medical University of South Carolina — Charleston, South Carolina, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Princess Margaret Hospital — Toronto, Ontario, Canada
- Seoul National University Hospital — Seoul, South Korea
- ASAN Medical Center — Seoul, South Korea
- Mass General Hospital — Boston, Massachusetts, United States
- Samsung Medical Center — Seoul, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.